Trial Search Results
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
Stanford is currently accepting patients for this trial.
- Device: Intermittent theta-burst stimulation (iTBS)
- Male or female, 18 to 75 years of age.
- Able to provide informed consent.
- Diagnosed with Major Depressive Disorder (MDD) or bipolar affective disorder 2 and
currently experiencing a Major Depressive Episode (MDE).
- prior exposure to rTMS
- Participants must qualify as "moderate or severe treatment refractory" using the
Maudsley staging method.
- Participants may continue antidepressant regimen, but must be stable for 6 weeks prior
to enrollment in the study. They must maintain that same antidepressant regimen
throughout the study duration.
- Participants are required to have a stable psychiatrist for the duration of study
- History of MI, CABG, CHF, or other cardiac history
- Any neurological conditions
- History of epilepsy
- Independent sleep disorder
- Autism Spectrum Disorder
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study